

Amoxibactin 50 mg tablets for dogs and cats

Authorised

- Amoxicillin trihydrate

Product identification

Medicine name:

Amoxibactin 50 mg tablets for dogs and cats

Active substance:

Amoxicillin trihydrate

Target species:

Dog

Cat

Route of administration:

Oral use

Product details

Active substance and strength:

Amoxicillin trihydrate

57.50 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ01CA04

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Netherlands

Available in:

Netherlands

Package description:

Cardboard box of 9 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 8 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 7 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 6 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 50 Aluminium - PVC/PE/PVDC blisters of 10 tablets

Cardboard box of 5 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 4 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 3 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 25 Aluminium - PVC/PE/PVDC blisters of 10 tablets

Cardboard box of 2 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 10 Aluminium - PVC/PE/PVDC blisters of 10 tablets

Cardboard box of 1 Aluminium - PVC/PE/PVDC blister of 10 tablets.

Cardboard box containing 10 separate cardboard boxes, each containing 1 blister of 10 tablets

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Le Vet. Beheer B.V.

Marketing authorisation date:

12/11/2014

Manufacturing sites for batch release:

Lelypharma B.V.

Responsible authority:

Medicines Evaluation Board

Authorisation number:

REG NL 114510

Date of authorisation status change:

31/01/2022

Reference member state:

Netherlands

Procedure number:

NL/V/0186/001

Concerned member states:

Austria Belgium Cyprus Czechia Denmark Estonia Finland France Germany
Greece Hungary Iceland Ireland Italy Latvia Lithuania Luxembourg Norway
Poland Portugal Romania Slovakia Spain Sweden

United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.